Education
About Us
Working with TipRanks
Follow Us
Odonate Inc (ODTC)
:ODTC
ODTC Stock Chart & Stats
$150000.00
$50.00(0.29%)
At close: 4:00 PM EST
$150000.00
$50.00(0.29%)
Day’s Range― - ―
52-Week Range$136,000.00 - $176,040.00
Previous CloseN/A
Volume3.00
Average Volume (3M)0.00
Market Cap
$54.85B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.79
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding365,650
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
ODTC FAQ
What was Odonate Inc’s price range in the past 12 months?
Odonate Inc lowest stock price was $136000.00 and its highest was $176040.00 in the past 12 months.
What is Odonate Inc’s market cap?
Odonate Inc’s market cap is $54.85B.
When is Odonate Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Odonate Inc’s earnings last quarter?
Currently, no data Available
Is Odonate Inc overvalued?
According to Wall Street analysts Odonate Inc’s price is currently Overvalued.
Does Odonate Inc pay dividends?
Odonate Inc does not currently pay dividends.
What is Odonate Inc’s EPS estimate?
Odonate Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Odonate Inc have?
Odonate Inc has 365,650 shares outstanding.
What happened to Odonate Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Odonate Inc?
Currently, no hedge funds are holding shares in ODTC
Company Description
Odonate Inc
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.